Filing Details

Accession Number:
0001237648-21-000040
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-09 16:20:58
Reporting Period:
2021-08-06
Accepted Time:
2021-08-09 16:20:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1038133 Heska Corp HSKA In Vitro & In Vivo Diagnostic Substances (2835) 770192527
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1724324 Catherine Grassman 3760 Rocky Mountain Avenue
Loveland CO 80538
Evp, Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-06 5,000 $69.77 8,986 No 4 M Direct
Common Stock Disposition 2021-08-06 4,679 $260.15 4,307 No 4 S Direct
Common Stock Disposition 2021-08-06 271 $261.23 4,036 No 4 S Direct
Common Stock Disposition 2021-08-06 50 $263.25 3,986 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-08-06 5,000 $0.00 5,000 $69.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
701 2018-03-07 2028-03-06 No 4 M Direct
Footnotes
  1. The price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.00 to $260.85. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which each transaction was effected.
  2. The price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.00 to $261.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which each transaction was effected.